E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients 18 - 65 years old with newly diagnosed non-cutanous, non leukemic Peripheral T- cell lymphoma, except alk-protein positive anaplastic large cell lymphoma. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042971 |
E.1.2 | Term | T-cell lymphoma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of the addition af Mab Campath s.c. to 2 Weekly CHOP 14 ( Chemotherapy) in terms of event free survival (EVS). |
|
E.2.2 | Secondary objectives of the trial |
¨ To assess the effect of the addition of alemtuzumab s.c. to 6 courses of 2-weekly CHOP14 in term of overall survival (OS), progression-free survival (PFS) and overall response rates (ORR, i.e. CR/CRu/PR). Assessment of ORR means evaluating eligibility to autologous stem cell transplantation. ¨ To evaluate the safety of the addition of alemtuzumab s.c. combined with 2-weekly CHOP with respect to the incidence of severe opportunistic infections and infections due to neutropenia as well as the adherence to protocol as defined in
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
9.1.1 Inclusion criteria ¨ Previously untreated patients with newly diagnosed peripheral T-cell lymphoma of stage I bulk (≥ 7.5 cm) and stages II to IV. ¨ Patients with a confirmed histologic diagnosis of peripheral T-cell NHL according to the WHO classification (Appendix C): ü Peripheral T-cell lymphoma, unspecified (PTCL NOS) ü Angioimmunoblastic T-cell lymphoma ü Enteropathy-type T cell lyphoma ü Primary systemic, alk-negative anaplastic large cell lymphoma (T- or null phenotype) ü Subcutaneous panniculitis-like T-NHL ü Hepatosplenic gd T-cell lymphoma ü Extranodal NK/T cell lymphoma, nasal type ¨ Age 18-65 years at time or randomization ¨ Life expectancy of 3 months or longer ¨ WHO performance status (PS) 0, 1 or 2 at the time of randomization (see appendix D). However, PS 3 will be acceptable if lymphoma-related. ¨ Measurable disease ¨ Written informed consent
|
|
E.4 | Principal exclusion criteria |
¨ Patients with NK/T-NHL of the following type: ü Precursor T cell lymphoblastic lymphoma/leukemia ü All mature T cell leukemias (T-PLL, ATLL, NK cell leukemia, T-LGL) ü Alk-positive anaplastic large cell lymphoma ü Blastic NK cell lymphoma ¨ Known hypersensitivity to murine or chimeric antibodies or proteins ¨ Severe cardiac dysfunction (NYHA classification II-IV, Appendix H) or LVEF < 45 % ¨ Significant renal dysfunction (serum creatinin > 2 times upper level), unless related to NHL ¨ Significant hepatic dysfunction (total bilirubin ³ 30 mmol/l or transaminases ³ 2.5 times normal level), unless related to NHL ¨ Suspected or documented Central Nervous System involvement by NHL ¨ Patients known to be HIV-positive ¨ Patients with active, uncontrolled infections, especially known seropositivity for HCV or HbsAg ¨ Patients with uncontrolled asthma or allergy, requiring steroid treatment ¨ Prior treatment with chemotherapy, radiotherapy or immunotherapy for this lymphoma, except local radiotherapy in case of extranodal NK/T cell lymphoma, nasal type ¨ History of active cancer during the past 5 years, except basal carcinoma of the skin or stage 0 cervical carcinoma ¨ Unwillingness or inability to comply with the protocol ¨ Simultaneous participation in any other study protocol
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the Event-free Survival (EFS). The EFS is defined by the time between day of randomization until one of the following events occurs, whichever comes first: · Disease progression during therapy · Institution of any additional unplanned anti-tumor treatment · Relapse after achievement of CR/CRu · Death due to any cause Patients who have not experienced an event at the time of analysis will be censored at the most recent date of disease assessment.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 80 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |